Finance chief exits as Annovis Bio (ANVS) CEO becomes acting CFO

Rhea-AI Filing Summary

Annovis Bio, Inc. reported that Andrew Walsh, its Vice President of Finance and Principal Financial Officer, resigned effective August 22, 2025. The company stated that his resignation did not result from any disagreement over operations, policies, or practices.

On August 15, 2025, the board unanimously appointed Chief Executive Officer Maria Maccecchini to also serve as Acting Chief Financial Officer. Annovis Bio indicated it is actively searching for a permanent Chief Financial Officer to fill the role.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001477845 0001477845 2025-08-11 2025-08-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 11, 2025

ANNOVIS BIO, INC.

(Exact Name of Registrant as Specified in Charter) 

Delaware	001-39202	26-2540421
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

101 Lindenwood Drive, Suite 225
Malvern, PA 19355

(Address of Principal Executive Offices, and Zip Code)

(484) 875-3192

Registrant’s Telephone Number, Including Area Code

                       Not Applicable                       s

(Former Name or Former Address, if Changed Since Last Report) 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	ANVS	New York Stock Exchange

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

On August 11, 2025, Annovis Bio, Inc. (the “Company”) received the resignation of Andrew Walsh as Vice President of Finance, the Company’s Principal Financial Officer, effective August 22, 2025. Mr. Walsh’s resignation did not arise from any disagreement with the Company or any matter relating to the Company’s operations, policies or practices. On August 15, 2025, the board of directors of the Company, by unanimous consent, appointed Maria Maccecchini, Chief Executive Officer of the Company, to serve as Acting Chief Financial Officer of the Company. The Company is actively searching for a replacement Chief Financial Officer.

Item 9.01 Financial Statements and Exhibits

Exhibit Number	Description
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ANNOVIS BIO, INC.
Date: August 15, 2025	By:	/s/ Maria Maccecchini
		Name: Maria Maccecchini
		Title: President and Chief Executive Officer

FAQ

Why did Annovis Bio (ANVS) file this Form 8-K?

Annovis Bio filed this Form 8-K to disclose the resignation of its Vice President of Finance and Principal Financial Officer, Andrew Walsh, and the appointment of CEO Maria Maccecchini as Acting Chief Financial Officer.

Who resigned from Annovis Bio (ANVS) and when is it effective?

Andrew Walsh, the Vice President of Finance and Principal Financial Officer, resigned from Annovis Bio with an effective date of August 22, 2025.

Did Andrew Walsh’s resignation at Annovis Bio (ANVS) involve any disagreement with the company?

The company stated that Mr. Walsh’s resignation did not arise from any disagreement with Annovis Bio regarding its operations, policies, or practices.

Who is serving as Acting Chief Financial Officer at Annovis Bio (ANVS)?

Maria Maccecchini, the Chief Executive Officer of Annovis Bio, was appointed by the board on August 15, 2025 to serve as Acting Chief Financial Officer.

Is Annovis Bio (ANVS) looking for a new permanent Chief Financial Officer?

Yes. Annovis Bio stated that it is actively searching for a replacement Chief Financial Officer to fill the role on a permanent basis.

What is Maria Maccecchini’s role at Annovis Bio (ANVS) after this change?

Following the change, Maria Maccecchini continues as President and Chief Executive Officer and is also serving as Acting Chief Financial Officer.